Table 1.
Baseline demographics and phenotypes in the investigated TAM-treated breast cancer patients (n = 40). Data are reported as the mean and 95% CI or percent
| Pre-menopausal (n = 20) |
Post-menopausal (n = 20) |
|
|---|---|---|
| Age at diagnosis (years) | 45.3 (44.70–45.90) | 66.8 (66.13–67.46) |
| BMI (kg/m2) | 29.58 (28.90–30.25) | 28.07 (27.58–28.56) |
| Color (%) | white (85), non-white (15) | white (75), non-white (25) |
| Cancer type (%) | ductal in situ (5), invasive ductal (90) and invasive lobular (5) | ductal in situ (0), invasive ductal (90) and invasive lobular (10) |
| HER2 status (%) | positive (20), negative (75) and unknown (5) | positive (10), negative (80) and unknown (10) |
| Chemotherapy (%) | Yes (20) and No (80) | Yes (5) and No (95) |
| CYP2D6 phenotype (MR) | 0.25 (0.21–0.30) | 0.24 (0.19–0.29) |
| Midazolam oral clearance (mL/min/kg) | 30.09 (21.55–42.02) | 24.10 (19.41–29.92) |
MR Metabolic ratio (plasma log metoprolol/α-hydroxymetoprolol)